# 8X8 Inc: financial statements, quarterly

EGHT · Nasdaq · CIK 1023731 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/eght.md) · [Financials](/companies/eght/financials.md) · [Filings](/companies/eght/filings.md) · [Insiders](/companies/eght/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eght/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [185](/filings/0001023731-24-000120.md) | [181](/filings/0001023731-25-000006.md) | [179 d](/filings/0001023731-26-000041.md) | [178](/filings/0001023731-25-000081.md) | [181](/filings/0001023731-25-000107.md) | [179](/filings/0001023731-26-000010.md) | [177 d](/filings/0001023731-26-000041.md) | [181](/filings/0001023731-26-000114.md) | [184](/filings/0001023731-25-000107.md) | [185](/filings/0001023731-26-000010.md) | [185 d](/filings/0001023731-26-000041.md) | [190](/filings/0001023731-26-000114.md) |
| Cost of revenue | $m | [57.1](/filings/0001023731-24-000120.md) | [56.2](/filings/0001023731-25-000006.md) | [57.0 d](/filings/0001023731-26-000041.md) | [57.2](/filings/0001023731-25-000081.md) | [57.8](/filings/0001023731-25-000107.md) | [57.8](/filings/0001023731-26-000010.md) | [57.0 d](/filings/0001023731-26-000041.md) | [60.9](/filings/0001023731-26-000114.md) | [64.8](/filings/0001023731-25-000107.md) | [66.8](/filings/0001023731-26-000010.md) | [68.2 d](/filings/0001023731-26-000041.md) | [73.8](/filings/0001023731-26-000114.md) |
| Gross profit | $m | [128](/filings/0001023731-24-000120.md) | [125](/filings/0001023731-25-000006.md) | [122 d](/filings/0001023731-26-000041.md) | [121](/filings/0001023731-25-000081.md) | [123](/filings/0001023731-25-000107.md) | [121](/filings/0001023731-26-000010.md) | [120 d](/filings/0001023731-26-000041.md) | [120](/filings/0001023731-26-000114.md) | [119](/filings/0001023731-25-000107.md) | [118](/filings/0001023731-26-000010.md) | [117 d](/filings/0001023731-26-000041.md) | [116](/filings/0001023731-26-000114.md) |
| Research and development | $m | [34.2](/filings/0001023731-24-000120.md) | [32.8](/filings/0001023731-25-000006.md) | [33.9 d](/filings/0001023731-26-000041.md) | [32.1](/filings/0001023731-25-000081.md) | [31.3](/filings/0001023731-25-000107.md) | [29.8](/filings/0001023731-26-000010.md) | [30.0 d](/filings/0001023731-26-000041.md) | [28.4](/filings/0001023731-26-000114.md) | [27.9](/filings/0001023731-25-000107.md) | [27.2](/filings/0001023731-26-000010.md) | [29.5 d](/filings/0001023731-26-000041.md) | [28.4](/filings/0001023731-26-000114.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.6)](/filings/0001023731-24-000120.md) | [(9.4)](/filings/0001023731-25-000006.md) | [(14.2) d](/filings/0001023731-26-000041.md) | [(1.4)](/filings/0001023731-25-000081.md) | [7.2](/filings/0001023731-25-000107.md) | [9.0](/filings/0001023731-26-000010.md) | [0.4 d](/filings/0001023731-26-000041.md) | [0.6](/filings/0001023731-26-000114.md) | [5.3](/filings/0001023731-25-000107.md) | [9.7](/filings/0001023731-26-000010.md) | [3.3 d](/filings/0001023731-26-000041.md) | [4.4](/filings/0001023731-26-000114.md) |
| Interest expense | $m | [10.1](/filings/0001023731-24-000120.md) | [10.0](/filings/0001023731-25-000006.md) | [9.7 d](/filings/0001023731-26-000041.md) | [10.0](/filings/0001023731-25-000081.md) | [7.9](/filings/0001023731-25-000107.md) | [5.8](/filings/0001023731-26-000010.md) | [5.2 d](/filings/0001023731-26-000041.md) | [4.0](/filings/0001023731-26-000114.md) | [4.8](/filings/0001023731-25-000107.md) | [4.6](/filings/0001023731-26-000010.md) | [4.4 d](/filings/0001023731-26-000041.md) | [4.2](/filings/0001023731-26-000114.md) |
| Income tax | $m | [(0.4)](/filings/0001023731-24-000120.md) | [0.5](/filings/0001023731-25-000006.md) | [2.1 d](/filings/0001023731-26-000041.md) | [0.7](/filings/0001023731-25-000081.md) | [1.1](/filings/0001023731-25-000107.md) | [0.9](/filings/0001023731-26-000010.md) | [0.5 d](/filings/0001023731-26-000041.md) | [1.3](/filings/0001023731-26-000114.md) | [0.2](/filings/0001023731-25-000107.md) | [0.5](/filings/0001023731-26-000010.md) | [(0.1) d](/filings/0001023731-26-000041.md) | [1.0](/filings/0001023731-26-000114.md) |
| Net income | $m | [(7.5)](/filings/0001023731-25-000006.md) | [(21.2)](/filings/0001023731-25-000006.md) | [(23.6) d](/filings/0001023731-26-000041.md) | [(10.3)](/filings/0001023731-26-000010.md) | [(14.5)](/filings/0001023731-26-000010.md) | [3.0](/filings/0001023731-26-000010.md) | [(5.4) d](/filings/0001023731-26-000041.md) | [(4.3)](/filings/0001023731-26-000114.md) | [0.8](/filings/0001023731-26-000010.md) | [5.1](/filings/0001023731-26-000010.md) | [0.1 d](/filings/0001023731-26-000041.md) | [(1.2)](/filings/0001023731-26-000114.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001023731-24-000120.md) | [(0.17)](/filings/0001023731-25-000006.md) | not reported | [(0.08)](/filings/0001023731-25-000081.md) | [(0.11)](/filings/0001023731-25-000107.md) | [0.02](/filings/0001023731-26-000010.md) | not reported | [(0.03)](/filings/0001023731-26-000114.md) | [0.01](/filings/0001023731-25-000107.md) | [0.04](/filings/0001023731-26-000010.md) | not reported | [(0.01)](/filings/0001023731-26-000114.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0001023731-24-000120.md) | [(0.17)](/filings/0001023731-25-000006.md) | not reported | [(0.08)](/filings/0001023731-25-000081.md) | [(0.11)](/filings/0001023731-25-000107.md) | [0.02](/filings/0001023731-26-000010.md) | not reported | [(0.03)](/filings/0001023731-26-000114.md) | [0.01](/filings/0001023731-25-000107.md) | [0.04](/filings/0001023731-26-000010.md) | not reported | [(0.01)](/filings/0001023731-26-000114.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [144](/filings/0001023731-24-000120.md) | [169](/filings/0001023731-25-000006.md) | [116](/filings/0001023731-26-000041.md) | [131](/filings/0001023731-25-000081.md) | [117](/filings/0001023731-25-000107.md) | [104](/filings/0001023731-26-000010.md) | [88.1](/filings/0001023731-26-000041.md) | [81.3](/filings/0001023731-26-000114.md) | [75.9](/filings/0001023731-25-000107.md) | [86.9](/filings/0001023731-26-000010.md) | [93.3](/filings/0001023731-26-000114.md) | [90.6](/filings/0001023731-26-000114.md) |
| Current assets | $m | [282](/filings/0001023731-23-000151.md) | [302](/filings/0001023731-24-000006.md) | [248](/filings/0001023731-25-000039.md) | [258](/filings/0001023731-24-000073.md) | [246](/filings/0001023731-24-000120.md) | [219](/filings/0001023731-25-000006.md) | [204](/filings/0001023731-26-000041.md) | [208](/filings/0001023731-25-000081.md) | [206](/filings/0001023731-25-000107.md) | [204](/filings/0001023731-26-000010.md) | [210](/filings/0001023731-26-000114.md) | [224](/filings/0001023731-26-000114.md) |
| Total assets | $m | [824](/filings/0001023731-23-000151.md) | [827](/filings/0001023731-24-000006.md) | [756](/filings/0001023731-25-000039.md) | [756](/filings/0001023731-24-000073.md) | [740](/filings/0001023731-24-000120.md) | [698](/filings/0001023731-25-000006.md) | [683](/filings/0001023731-26-000041.md) | [684](/filings/0001023731-25-000081.md) | [671](/filings/0001023731-25-000107.md) | [662](/filings/0001023731-26-000010.md) | [663](/filings/0001023731-26-000114.md) | [673](/filings/0001023731-26-000114.md) |
| Current liabilities | $m | [229](/filings/0001023731-23-000151.md) | [231](/filings/0001023731-24-000006.md) | [173](/filings/0001023731-25-000039.md) | [172](/filings/0001023731-24-000073.md) | [209](/filings/0001023731-24-000120.md) | [176](/filings/0001023731-25-000006.md) | [169](/filings/0001023731-26-000041.md) | [176](/filings/0001023731-25-000081.md) | [184](/filings/0001023731-25-000107.md) | [180](/filings/0001023731-26-000010.md) | [193](/filings/0001023731-26-000114.md) | [213](/filings/0001023731-26-000114.md) |
| Total liabilities | $m | [713](/filings/0001023731-23-000151.md) | [717](/filings/0001023731-24-000006.md) | [654](/filings/0001023731-25-000039.md) | [651](/filings/0001023731-24-000073.md) | [630](/filings/0001023731-24-000120.md) | [585](/filings/0001023731-25-000006.md) | [561](/filings/0001023731-26-000041.md) | [556](/filings/0001023731-25-000081.md) | [538](/filings/0001023731-25-000107.md) | [519](/filings/0001023731-26-000010.md) | [516](/filings/0001023731-26-000114.md) | [525](/filings/0001023731-26-000114.md) |
| Long-term debt | $m | not reported | not reported | [410](/filings/0001023731-25-000039.md) | not reported | [357](/filings/0001023731-24-000120.md) | [348](/filings/0001023731-25-000006.md) | [338](/filings/0001023731-26-000041.md) | [329](/filings/0001023731-25-000081.md) | [307](/filings/0001023731-25-000107.md) | [294](/filings/0001023731-26-000010.md) | [282](/filings/0001023731-26-000114.md) | [270](/filings/0001023731-26-000114.md) |
| Current portion of debt | $m | not reported | not reported | [0.0](/filings/0001023731-25-000039.md) | not reported | [39.4](/filings/0001023731-24-000120.md) | [16.5](/filings/0001023731-25-000006.md) | [11.6](/filings/0001023731-26-000041.md) | [6.6](/filings/0001023731-25-000081.md) | [19.2](/filings/0001023731-25-000107.md) | [26.7](/filings/0001023731-26-000010.md) | [39.2](/filings/0001023731-26-000114.md) | [37.3](/filings/0001023731-26-000114.md) |
| Shareholders' equity | $m | [110](/filings/0001023731-25-000006.md) | [110](/filings/0001023731-25-000006.md) | [102](/filings/0001023731-26-000041.md) | [105](/filings/0001023731-26-000010.md) | [110](/filings/0001023731-26-000010.md) | [113](/filings/0001023731-26-000010.md) | [122](/filings/0001023731-26-000114.md) | [128](/filings/0001023731-26-000114.md) | [133](/filings/0001023731-26-000010.md) | [143](/filings/0001023731-26-000010.md) | [147](/filings/0001023731-26-000114.md) | [148](/filings/0001023731-26-000114.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [17.5 d](/filings/0001023731-24-000120.md) | [22.4 d](/filings/0001023731-25-000006.md) | [12.7 d](/filings/0001023731-26-000041.md) | [18.1](/filings/0001023731-25-000081.md) | [12.3 d](/filings/0001023731-25-000107.md) | [27.2 d](/filings/0001023731-26-000010.md) | [5.9 d](/filings/0001023731-26-000041.md) | [11.9](/filings/0001023731-26-000114.md) | [8.8 d](/filings/0001023731-25-000107.md) | [20.7 d](/filings/0001023731-26-000010.md) | [14.4 d](/filings/0001023731-26-000041.md) | [17.0](/filings/0001023731-26-000114.md) |
| Capital expenditure | $m | [1.4 d](/filings/0001023731-24-000120.md) | [0.8 d](/filings/0001023731-25-000006.md) | [0.3 d](/filings/0001023731-26-000041.md) | [0.4](/filings/0001023731-25-000081.md) | [1.2 d](/filings/0001023731-25-000107.md) | [0.5 d](/filings/0001023731-26-000010.md) | [0.4 d](/filings/0001023731-26-000041.md) | [0.4](/filings/0001023731-26-000114.md) | [1.1 d](/filings/0001023731-25-000107.md) | [1.6 d](/filings/0001023731-26-000010.md) | [0.6 d](/filings/0001023731-26-000041.md) | [0.7](/filings/0001023731-26-000114.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001023731-24-000006.md) | [0.0 d](/filings/0001023731-26-000041.md) | [0.0](/filings/0001023731-25-000081.md) | [0.0 d](/filings/0001023731-25-000107.md) | [0.0 d](/filings/0001023731-26-000010.md) | [0.0 d](/filings/0001023731-26-000041.md) | [1.8](/filings/0001023731-26-000114.md) | [0.0 d](/filings/0001023731-25-000107.md) | [0.0 d](/filings/0001023731-26-000010.md) | [0.0 d](/filings/0001023731-26-000041.md) | [0.0](/filings/0001023731-26-000114.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [116](/filings/0001023731-23-000151.md) | [113](/filings/0001023731-24-000006.md) | [117](/filings/0001023731-24-000073.md) | [121](/filings/0001023731-24-000120.md) | [123](/filings/0001023731-25-000006.md) | [126](/filings/0001023731-25-000081.md) | [129](/filings/0001023731-25-000107.md) | [136](/filings/0001023731-26-000010.md) | [135](/filings/0001023731-26-000114.md) | [142](/filings/0001023731-25-000107.md) | [143](/filings/0001023731-26-000010.md) | [142](/filings/0001023731-26-000114.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 144,435,501 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001023731-26-000114.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.